Percutaneous Coronary Intervention: stenting with the ihtDEStiny® sirolimus eluting stent
Study summary
Prospective registry intended to evaluate clinical outcomes of ihtDEStiny drug eluting coronary stent.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* ≥18 years old
* PCI and stent implantation indication according to ESC Myocardial Revascularization Guidelines
* 1 or more stenosis at native coronary anatomy, in a 2-4mm vessel size, where 1 or more ihtDEStiny® drug eluting stent were implanted (or attempted to be implanted).
* Informed consent signed after PCI
Exclusion Criteria:
* Patient refusal to participate in the study
* Pregnancy
* Other DES implantation during index PCI, or 30 days before of after index PCI
* PCI at surgical grafts
* PCI for in-stent restenosis
* Killip class 3-4 Acute Coronary Syndromes (ACS)
* High bleeding risk with dual antiplatelet intolerance for at least 3 months (or 6 months for ACS PCI)
* Allergy or hypersensitivity to sirolimus
* Patients requiring surgery (cardiac or non-cardiac) in the next 3 months after index PCI
* Patients with life expectancy \<2 years
* Patients included in other trials or clinical studies
Primary outcome measure(s)
Target Lesion Failure (TLF) — 2 years Rate of target lesion failure
Target Lesion Failure (TLF) — 5 years Rate of target lesion failure
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
